Developing Innovative Therapies for
Patients With Kidney and Vascular Diseases


Proteon is developing first-in-class therapeutics to improve
the health of patients with kidney and vascular diseases


Learn More


Focused on Vascular Access Failure
in Hemodialysis


Proteon is seeking to address vascular access failure,
a significant medical need for hemodialysis patients


Learn More


Learn More About
Investigational Vonapanitase


An investigational drug in Phase 3 clinical developmentto improve patency
after surgical creation of an arteriovenous fistula (AVF) for hemodialysis


Watch Now

WHO WE ARE

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in a Phase 3 clinical trial in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis and in a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).

 

Learn More